|
|
|
MIRA INFORM REPORT
|
Report No. : |
503745 |
|
Report Date : |
12.04.2018 |
IDENTIFICATION DETAILS
|
Name : |
OSAKA SYNTHETIC CHEMICAL LABORATORIES INC |
|
|
|
|
Registered Office : |
1-1-2 Nishinomiyahama Nishinomiya Hyogo-Pref 662-0934 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.03.2018 |
|
|
|
|
Date of Incorporation : |
March, 1961 |
|
|
|
|
Com. Reg. No.: |
1400-01-068188 (Hyogo-Nishinomiya) |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki Kaisha) |
|
|
|
|
Line of Business : |
Manufacturer of Test Reagents, Pharmaceuticals, Industrial Chemicals. |
|
|
|
|
No. of Employees : |
240 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
JAPAN - ECONOMIC OVERVIEW
Over the past 70 years, government-industry cooperation, a strong work ethic, mastery of high technology, and a comparatively small defense allocation (slightly less than 1% of GDP) have helped Japan develop an advanced economy. Two notable characteristics of the post-World War II economy were the close interlocking structures of manufacturers, suppliers, and distributors, known as keiretsu, and the guarantee of lifetime employment for a substantial portion of the urban labor force. Both features have significantly eroded under the dual pressures of global competition and domestic demographic change.
Measured on a purchasing power parity basis that adjusts for price differences, Japan in 2017 stood as the fourth-largest economy in the world after first-place China, which surpassed Japan in 2001, and third-place India, which edged out Japan in 2012. For three postwar decades, overall real economic growth was impressive - a 10% average in the 1960s, 5% in the 1970s, and 4% in the 1980s. Growth slowed markedly in the 1990s, averaging just 1.7%, largely because of the aftereffects of inefficient investment and the collapse of an asset price bubble in the late 1980s, which entailed considerable time for firms to reduce excess debt, capital, and labor. Modest economic growth continued after 2000, but the economy has fallen into recession four times since 2008.
Japan enjoyed an uptick in growth in 2013 on the basis of Prime Minister Shinzo ABE’s “Three Arrows” economic revitalization agenda - dubbed “Abenomics” - of monetary easing, “flexible” fiscal policy, and structural reform. Led by the Bank of Japan’s aggressive monetary easing, Japan is making modest progress in ending deflation, but demographic decline – a low birthrate and an aging, shrinking population – poses a major long-term challenge for the economy. The government currently faces the quandary of balancing its efforts to stimulate growth and institute economic reforms with the necessity of addressing its sizable public debt, which stands at 235% of GDP. To help raise government revenue, Japan adopted legislation in 2012 to gradually raise the consumption tax rate. However, the first such increase, in April 2014, led to another recession, so Prime Minister ABE has twice postponed the next increase, now scheduled for October 2019. Structural reforms to unlock productivity are seen as central to strengthening the economy in the long-run.
Scarce in critical natural resources, Japan has long been dependent on imported energy and raw materials. After the complete shutdown of Japan’s nuclear reactors following the earthquake and tsunami disaster in 2011, Japan's industrial sector has become even more dependent than before on imported fossil fuels. However, ABE’s government is seeking to restart nuclear power plants that meet strict new safety standards and is emphasizing nuclear energy’s importance as a base-load electricity source. In August 2015, Japan successfully restarted one nuclear reactor at the Sendai Nuclear Power Plant in Kagoshima prefecture, and several other reactors around the country have since resumed operations; however, opposition from local governments has delayed several more restarts that remain pending. Reforms of the electricity and gas sectors, including full liberalization of Japan’s energy market in April 2016 and gas market in April 2017, constitute an important part of Prime Minister Abe’s economic program.
In October 2015, Japan and 11 trading partners reached agreement on the Trans-Pacific Partnership (TPP), a pact that had promised to open Japan's economy to increased foreign competition and create new export opportunities for Japanese businesses. Japan was the first country to ratify the TPP in December 2016; the United States signaled its withdrawal from the TPP in January 2017, and in November 2017 the remaining 11 countries agreed on the core elements of a modified agreement, which they renamed the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP).
|
Source
: CIA |
Company
name and address
OSAKA SYNTHETIC CHEMICAL LABORATORIES INC
REGD NAME: KK
Osaka Gosei Yuki Kagaku Kenkyusho
MAIN OFFICE: 1-1-2
Nishinomiyahama Nishinomiya Hyogo-Pref 662-0934 JAPAN
Tel: 0798-22-5840 Fax: 0798-22-5845
E-Mail address: (thru the URL)
ACTIVITIES
Mfg of test
reagents, pharmaceuticals, industrial chemicals
BRANCHES
Nil
FACTORIES
Hyogo (3), Okayama
OFFICERS
YASUAKI MATSUURA,
PRES Zen’ichi Kogame, v pres
Akitoshi Ando, mgn
dir Shingo Matsumoto, dir
Yukihide Koyama,
dir Hitoshi Yawara, dir
Yen Amount: In million Yen, unless otherwise stated
SUMMARY
FINANCES FAIR A/SALES Yen 6,333
M
PAYMENTS REGULAR CAPITAL Yen
35 M
TREND UP WORTH Yen
3,286 M
STARTED 1981 EMPLOYES 240
COMMENT
MFR OF REAGENTS, PHARMACEUTICALS, OWNED BY
KANEKA CORP.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD
FOR ORDINARY BUSINESS ENGAGEMENTS.
HIGHLIGHTS
The subject
company was established on the basis of a division separated from Kaneka
Corporation (See REGISTRATION). The firm specialized in mfg pharmaceuticals,
materials, intermediates, test reagents, industrial chemicals, other. Goods are exported. Clients include chemical mfrs, pharmaceutical
mfrs, wholesalers, other, nationwide
FINANCIAL
INFORMATION
Financials are
disclosed only partially.
The sales volume for
Mar/2017 fiscal term amounted to Yen 6,333 million, a 4% up from Yen 6,100
million in the previous term. The
recurring profit was posted at Yen 904 million and the net profit at Yen 701
million, respectively, compared with Yen 613 million net profit a year ago.
For the term that
ended Mar 2018 the recurring profit was projected at Yen 920 million and the
net profit at Yen 710 million, respectively, on a 5% rise in turnover, to Yen
6,650 million. Final results are yet to
be released.
The financial situation
is considered FAIR and good for ORDINARY business engagements.
REGISTRATION
Date
Registered: Mar 1961
Regd
No.: 1400-01-068188
(Hyogo-Nishinomiya)
Legal
Status: Limited Company (Kabushiki Kaisha)
Authorized: 8,000 shares
Issued:
3,160 shares
Sum:
Yen
35 million
Major shareholders (%): Kaneka Corp* (100)
*.. Leading mfr of PVC resins, Osaka, founded
1949, listed Tokyo, Nagoya S/E’s, capital Yen
33,046 million, sales Yen 548,222 million, operating profit Yen 33,164 million,
recurring profit Yen 27,426 million, net profit Yen 20,484 million, total
assets Yen 636,528 million, net worth Yen 326,499 million, employees 9,666,
pres Mamoru Kadokura
Nothing
detrimental is known as to the commercial morality of executives.
OPERATION
Activities: Manufactures
pharmaceuticals, materials, intermediates (70%), test reagents (20%),
industrial chemicals, others (--10%)
Clients: [Mfrs,
wholesalers] Kanaka Corp, Sanofi KK, Takeda Chemical Ind, Mitsubishi Chemical,
Japan Tobacco Inc, Mitsubishi Tanabe Pharma Corp, Sumitomo Dainippon Pharma Co,
Nippon Shinyaku Co, other
No. of accounts: 350
Domestic areas of activities: Nationwide
Suppliers: [Mfrs, wholesalers]
Nagase & Co, Inoue Mago Co, Nakano Fine Chemical, Shimizu Ind, Fuji
Chemicals, Wako Pure Chemical Ind, Kenko Corp, Kanto Kagaku, Nippon Fine
Chemical, other
Payment
record: Regular
Location: Business area in Osaka. Office premises at
the caption address are owned and maintained satisfactory.
Bank
References:
SMBC
(Nishinomiya)
Relations:
Satisfactory
FINANCES
(In Million Yen)
|
Terms Ending: |
|
31/03/2018 |
31/03/2017 |
31/03/2016 |
31/03/2015 |
|
Annual
Sales |
|
6,650 |
6,333 |
6,100 |
5,800 |
|
Recur.
Profit |
|
920 |
904 |
.. |
.. |
|
Net
Profit |
|
740 |
701 |
613 |
616 |
|
Total
Assets |
|
|
7,634 |
6,278 |
6,205 |
|
Net
Worth |
|
|
3,286 |
2,892 |
2,585 |
|
Capital,
Paid-Up |
|
|
35 |
35 |
35 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
|
(%) |
(%) |
(%) |
(%) |
|
S.Growth Rate |
|
5.01 |
3.82 |
5.17 |
18.37 |
|
Current Ratio |
|
|
.. |
.. |
.. |
|
N.Worth Ratio |
|
|
43.04 |
46.07 |
41.66 |
|
N.Profit/Sales |
|
11.13 |
11.07 |
10.05 |
10.62 |
Notes: Financials are only partially disclosed.
Forecast (or
estimated) figures for the 31/03/2018 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 65.13 |
|
|
1 |
INR 92.52 |
|
Euro |
1 |
INR 80.59 |
|
Yen |
1 |
INR 0.61 |
Note:
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.